Heart and Vascula...
Find tag "Ridker"
32.0K views | +1 today
Heart and Vascular Health
Media, News & Topics on prevention, diagnosis & treatment of cardiovascular disease
Your new post is loading...
Your new post is loading...
Scooped by Seth Bilazarian, MD

Paul Ridker on Inflammation and Residual CV Risk

Paul Ridker on Inflammation and Residual CV Risk | Heart and Vascular Health | Scoop.it

Dr. Bilazarian interviews Dr. Paul Ridker on the inflammation hypothesis and 2 ongoing trials in this area: the National Heart, Lung, and Blood Institute (NHLBI)-funded Cardiovascular Inflammation Reduction Trial (CIRT),[1] which is testing whether taking low-dose methotrexate reduces myocardial infarction (MI), stroke, or death in people with type 2 diabetes or metabolic syndrome who have had a heart attack or have stable coronary artery disease; and the Novartis-sponsored Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS),[2] which is assessing whether blocking the proinflammatory cytokine interleukin (IL)-1β with canakinumab, as compared with placebo, can reduce rates of recurrent MI, stroke, and cardiovascular death in patients post-MI with elevated high-sensitivity C-reactive protein (CRP; ≥ 2 mg/L).

Seth Bilazarian, MD's insight:

Paul Ridker provides a great primer for clinicians & patients on the status of trials investigating the links between inflammation and cardiovascular disease. He reviews the background and status of the two large randomized clinical outcomes trials he leads: CANTOS & CIRT.


Other resources:

1.  slides from Dr. Ridker at  https://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm_426676.pdf


2. CIRT trial http://www.thecirt.org/


3,  CANTOS trial http://www.thecantos.org/

No comment yet.
Scooped by Seth Bilazarian, MD

Inflammation, Statin Therapy, and hsCRP: Initial Observations

Lecture slides form Dr. Paul Ridker at  ATVB 2011 – Inflammation, Immunity, and Atherosclerosis on Inflammation and Atherothrombosis: Where will new trials take us?


Great slide set for review of Inflammation, Statin Therapy, and hsCRP: Initial Observations


It discusses the as yet unanswered question can targeted Anti-Inflammatory Therapy Reduce Cardiovascular Risk?


Builds the case for why IL-1β inhibition is an attractive target based on experimental data and models and the current understanding of IL-1 and its potential roles in atherogenesis.  Also reviews the candidate therapy, Canakinumab (Ilaris, Novartis) being investigagted in the CANTOS trial.


Brief conclusion:

Is there evidence that individuals with elevated levels of inflammatory biomarkers are at high vascular risk even when other risk factors are acceptable? => YES
Is there evidence that individuals identified at increased risk due to inflammation benefit from a therapy they otherwise would not have received? => YES
Is there evidence that reducing inflammation will reduce vascular events? =>



For patients with a prior histroy of heart attack (MI) interested in learning more about the CANTOS trial being conducted at PMA, under the direction of Dr. Sunny Srivistava in Haverhill see...



No comment yet.